Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sip of science: probiotic milk drink targets gut and metabolism

NCT ID NCT07793487

Disease control Sponsor: Warsaw University of Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

Researchers are testing whether a specially fermented milk drink with probiotic bacteria can improve symptoms of irritable bowel syndrome (IBS) and metabolic syndrome. The study will include 80 adults with IBS or at least one sign of metabolic syndrome, such as high blood pressure or high cholesterol, along with abdominal obesity. Participants will drink the probiotic milk as part of their diet, and researchers will track changes in gut symptoms, quality of life, and metabolic markers like blood sugar and cholesterol. The goal is to see if this functional dairy product can be a helpful part of dietary therapy for these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A fermented milk drink with added Levilactobacillus brevis B1 probiotic bacteria
What this could lead to
If it works, this could offer a simple dietary approach to managing both IBS symptoms and metabolic issues like high blood sugar or cholesterol.
What could go wrong
This is an early-stage study with a small number of participants, so results may not apply broadly. The drink's effects could be modest, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI \> 18.5 and \< 25 kg/m² * adults \> 18 years of age, * diagnosed with irritable bowel syndrome or at least one criterion of metabolic syndrome, in addition to abdominal obesity (hypertension and/or hyperlipidemia and/or glucose intolerance), * not taking pro- and/or prebiotic supplements Exclusion Criteria: * Presence of chronic diseases such as cancer, kidney, liver, and thyroid disease, autoimmune diseases, and food allergies requiring the complete elimination of dairy products, * Type 1 and type 2 diabetes treated with insulin * Antibiotic therapy * Consumption of a vegetarian diet or a low-energy diet (pharmacological treatment of obesity) and/or diets, e.g., high-fat, high-protein diets * possession of electrostimulation and/or measurement devices that prevent measurement * lack of informed consent to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBS - irritable bowel syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome irritable bowel syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBS - irritable bowel syndrome Metabolic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW)

    Warsaw, 02-776, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.